Robust IPO activity in 2026, with over $250 billion raised through mid-year across dozens of U.S. listings, reflects strong equity market demand and a broad pipeline of growth companies, particularly in AI and technology. SpaceX's record June offering and recent filings or pricings by firms such as Oura and ADARx Pharmaceuticals underscore sustained momentum into the final quarter. Market-implied odds for specific companies pricing before December 31, 2026, incorporate factors like confidential S-1 submissions, valuation discipline amid elevated private multiples, and potential catalysts including earnings reports or regulatory windows. Some larger names have signaled delays into 2027 due to market capacity concerns, while smaller and mid-sized deals continue to advance amid supportive Treasury yields and risk appetite.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · UpdatedPerplexity remains private with no confirmed IPO before the deadline
Available reporting continues to describe Perplexity as private and its CEO’s stated target as 2028. No official IPO completion or filing by the market deadline was found in the supplied material, supporting the low endpoint price.

































Beware of external links.
Beware of external links.
Frequently Asked Questions